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Appropriate growth and development of the endometrium across the menstrual cycle
is key for a woman’s quality of life and reproductive well-being. Recurrent pregnancy
loss (RPL) and heavy menstrual bleeding (HMB) affect a significant proportion of the
female population worldwide. These endometrial pathologies have a significant impact
on a woman’s quality of life as well as placing a high economic burden on a country’s
health service. An underlying cause for both conditions is unknown in approximately
50% of cases. Previous research has demonstrated that aberrant endometrial vascular
maturation is associated with both RPL and HMB, where it is increased in RPL but
reduced in HMB. TGFβ1 is one of the key growth factors that regulate vascular
maturation, by inducing phenotypic switching of vascular smooth muscle cells (VSMCs)
from a synthetic phenotype to a more contractile one. Our previous data demonstrated
an increase in TGFβ1 in the endometrium of RPL, while others have shown a decrease in
women with HMB. However, TGFβ1 bioavailability is tightly controlled, and we therefore
sought to perform an extensive immunohistochemical analysis of different components
in the pathway in the endometrium of normal controls, women with HMB or RPL. In
addition, two in vitro models were used to examine the role of TGFβ1 in endometrial
vascular maturation and endothelial cell (EC):VSMC association. Taken all together,
the immunohistochemical data suggest a decrease in bioavailability, receptor binding
capacity, and signaling in the endometrium of women with HMB compared with controls.
In contrast, there is an increase in the bioavailability of active TGFβ1 in the endometrium
of women with RPL compared with controls. Endometrial explants cultured in TGFβ1
had an increase in the number of vessels associated with contractile VSMC markers,
although the total number of vessels did not increase. In addition, TGFβ1 increased
EC:VSMC association in an in vitro model. In conclusion, TGFβ1 is a key regulator of
endometrial vascular maturation and could be considered as a therapeutic target for
women suffering from HMB and/or RPL.
Keywords: endometrium, heavy menstrual bleeding, recurrent pregnancy loss, transforming growth factor beta,
VSMC differentiation
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INTRODUCTION
The endometrium is one of the most dynamic tissues in the
human body, undergoing a repetitive cycle of proliferation,
differentiation and breakdown every month during the
menstrual cycle. After menstruation, the endometrium
functionalis is regenerated from the remaining endometrium
basalis, a niche for endometrial stem cells and stumps of the
endometrial vasculature. Increasing evidence suggests that
dysregulated regeneration of the endometrium may contribute
to conditions affecting a woman’s reproductive health, e.g.,
recurrent pregnancy loss (RPL) and heavy menstrual bleeding
(HMB). Abnormal development and flow in these endometrial
blood vessels has been implicated in various reproductive
disorders including RPL, recurrent implantation failure (RIF),
unexplained infertility, and HMB (Goswamy et al., 1988; Steer
et al., 1994; Habara et al., 2002; Quenby et al., 2009).
Heavy menstrual bleeding (HMB) affects approximately 10
million women annually in the United States, including 30% of
women of reproductive age, and significantly impacts a woman’s
quality of life and impacts society in terms of health care costs
and lost productivity of the female workforce (Hapangama and
Bulmer, 2016; NICE, 2018; Critchley et al., 2020). While HMB
may result from clinical conditions such as uterine fibroids
and adenomyosis, approximately 50% of the cases remain
unexplained (Rees, 1987; Davis and Sparzak, 2020) and current
treatment options often compromise fertility either temporarily
or permanently. We and others have previously demonstrated
that vascular structure and maturation is anomalous in the
endometrium of women with HMB (Abberton et al., 1999a,b;
Hurskainen et al., 1999; Rogers and Abberton, 2003; Biswas
Shivhare et al., 2014, 2018).
Recurrent pregnancy loss is defined as two or more
consecutive pregnancy losses; many cases are idiopathic (Quenby
and Farquharson, 1993; Rai and Regan, 2006), although an altered
endometrial environment may be a contributory factor to these
idiopathic cases (Brosens and Gellersen, 2010). We and others
have shown that women with a history of RPL have increased
endometrial blood vessel maturity and blood flow (demonstrated
by uterine artery Doppler) (Quenby et al., 2009; El-Azzamy et al.,
2018). Embryo implantation occurs in a low oxygen environment
(2–3% O2) (Yedwab et al., 1976; Rodesch et al., 1992), with
oxygen levels in the intervillous space rising to 6–8% O2 between
10 and 12 weeks gestation (Jauniaux et al., 2000). Inappropriate
maternal blood flow to the intervillous space may be underpinned
by several different pathologies and has been proposed to be a
final common pathway in both sporadic miscarriage and RPL
(Jauniaux et al., 2000). Therefore, we propose that the described
changes in the endometrial vasculature in women with a history
of RPL may lead to excess oxygen at the early implantation
site, resulting in oxidative stress damage to the developing
embryo and placenta.
The carefully timed cyclic features of angiogenesis and
remodeling of monthly endometrial growth and regression
results from a complex network of interactions between
hormones and pro- or anti-angiogenic growth factors (Rogers
et al., 2009). Although estrogen and progesterone are the primary
regulators of endometrial angiogenesis (Iruela-Arispe et al., 1999;
Hague et al., 2002), their action is indirectly mediated by several
growth factors expressed by the diverse cell population in the
endometrium (Hapangama et al., 2015; Kamal et al., 2016).
The endometrium is a rich source of angiogenic growth factors
(AGFs), which show temporal changes in expression patterns
across the menstrual cycle (Lash et al., 2012).
TGFβ1 is secreted as a latent form, its activation and
consequent bioavailability is tightly regulated in a multistep
process which includes secretion, storage and interaction with
ECM components, release from ECM and finally activation
prior to receptor binding (ten Dijke and Arthur, 2007). The
inactive TGFβ peptide consists of a TGFβ dimer, covalently
bound to the latency-associated peptide (LAP) forming the
small latent complex (SLC), which can subsequently covalently
attach to the large latent TGFβ-binding protein (LTBP1) to
form the large latent complex (LLC) (Kanzaki et al., 1990;
Saharinen et al., 1996; Maroni and Davis, 2011). The LLC
binds to microfibrils and ECM via the LTBP. The degradation
of these microfibrils via inflammatory proteolytic enzymes
like elastase displaces the LLC from ECM, prior to TGFβ
activation (Chaudhry et al., 2007; ten Dijke and Arthur, 2007).
Following displacement from ECM, the mature TGFβ dimer is
released from the LAP and activated by matrix metalloproteases
2 and 9 (MMP2, MMP9), thrombospondin-1 (THBS1) or
integrins in a cell-specific manner, prior to binding to their
signaling receptors (Crawford et al., 1998; Annes et al., 2003;
Sheppard, 2005; ten Dijke and Arthur, 2007). Active TGFβ dimer
signaling is mediated via two pairs of transmembrane receptor
serine/threonine kinases knows as the TGFβ type I (TGFβRI)
and TGFβ type II (TGFβRII) and/or accessory receptors
TGFβRIII (betaglycan) and endoglin (on ECs). One TGFβRII and
two distinct TGFβRI receptors; endothelium restricted activin
receptor-like kinase (ALK)1 and widely expressed ALK5, are
indicated in the TGFβ signaling pathway. Active TGFβ binds to
TGFβRII, which recruits, phosphorylates and activates TGFβRI
(ALK5), which in turn phosphorylates Smad transcription factors
Smad2 and 3, which in turn interact either with SMAD4 to
regulate targeted gene expression or with Smad7 resulting in
inhibition of this cascade (ten Dijke and Arthur, 2007; Massagué
et al., 2008). One of the functions of TGFβ1, is regulation
of vascular smooth muscle cell (VSMC) recruitment as well
as phenotypic switching from a synthetic to more contractile
cell type, which is associated with more mature blood vessels
(Lebrin et al., 2005). TGFβ1 and its receptors are expressed
in the endometrium across the menstrual cycle, and TGFβ1 is
also increased in RPL, a condition associated with increased
vascular maturation (Lash et al., 2012). Expression of TGFβ1 has
previously been shown to be either unchanged (Abberton et al.,
1999b) or reduced in the endometrium of women with HMB
(Maybin et al., 2017).
We, and others, have previously demonstrated altered
endometrial vascular development in women with HMB and RPL
(Abberton et al., 1999b; Quenby et al., 2009; Biswas Shivhare et al.,
2014, 2018). We have also shown that TGFβ1 immunoreactivity
is increased in the endometrium of RPL (Lash et al., 2012). We
therefore hypothesized that expression of TGFβ1, or its receptors,
is reduced in the endometrium of women with HMB. We also
aimed to further explore the expression of members of the TGFβ1
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activation and signaling cascade in endometrium derived from
women with a history of RPL and HMB.
MATERIALS AND METHODS
Samples
Endometrial biopsies were obtained with informed consent
from women undergoing hysterectomy at the Royal Victoria
Infirmary, Newcastle upon Tyne, United Kingdom; Liverpool
Women’s Hospital, Liverpool, United Kingdom; or Guangzhou
Women and Children’s Medical Center (GWCMC), Guangzhou,
China. HMB was defined as excessive menstrual blood loss
which interferes with the woman’s physical, emotional, social,
and material quality of life, and which can occur alone or in
combination with other symptoms (NICE, 2018). In line with the
hospital guidelines, empirical blood-loss measurements were not
taken, and all cases were idiopathic. All women in the HMB group
had unexplained disease, with no known underlying pathologies.
RPL was defined as 2 or more consecutive miscarriages with
no known causes after extensive examination. The control
group was fertile women without any uterine pathology
potentially associated with known endometrial abnormality
(e.g., endometriosis, adenomyosis, leiomyomata, heavy irregular
bleeding, or HMB) undergoing hysterectomy due to prolapse,
cystocele, rectocele, urinary, or stress incontinence. Any women
who had received hormone treatment within 3 months prior to
the operation were excluded from the study. The menstrual cycle
phase was staged according to standard morphological criteria
(Noyes et al., 1975) by specialist gynecology histopathologists.
Endometrial biopsies (N = 5, in each of proliferative-
early secretory (P/ES), and mid-late secretory (MS/LS) phases)
were obtained from both control and women with HMB.
Pipelle biopsies were taken from women with RPL at day
7–9 after the luteinizing hormone (LH) surge as previously
described (Lash et al., 2012). The biopsies were fixed in 10%
neutral buffered formalin for 24–48 h, routinely processed and
embedded in paraffin wax, and 3 µm serial sections were
cut for immunohistochemistry. The study was approved by
Newcastle and North Tyneside Research Ethics Committee
(Ref: 10/H0906/71), Liverpool Adult Ethics Committee (Ref:
09/H1005/55), and the GWCMC Ethics Committee (Ref:
2016021633). Patient demographics are shown in Table 1.
Endometrial biopsies for explant culture were obtained from
women undergoing hysterectomy at the Royal Victoria Infirmary,
Newcastle upon Tyne. Following surgery, the hysterectomy
specimen was inspected by a clinical pathologist who excluded
any suspicion of significant endometrial or cervical pathology
and excised a block of endometrium or myometrium with
overlying endometrium measuring approximately 2 × 2 cm. In
the research laboratory the biopsy was further dissected into
five approximately equal sections, placed into separate wells
of a 48-well plate and cultured in control medium [DMEM-
F12 containing 10% FBS, penicillin/streptomycin, L-glutamine
(Life Technologies, Paisley, United Kingdom)], TGFβ1 (1 ng/ml,
10 ng/ml; Peprotech EC Ltd., London, United Kingdom) or
anti-TGFβ1 antibody (10 ng/ml, AbCam) for 72 h, with
treatment medium being changed after every 24 h. Controls
contained 2 µM citric acid diluted in the appropriate culture
medium. After 72 h, the tissue sections were removed from
the plate, immediately fixed in neutral buffered formalin in five
separately labeled containers and FFPE sections prepared for
immunohistochemistry analysis.
Immunohistochemistry
Paraffin sections (3 µm) were dewaxed in xylene, rehydrated
through descending concentrations of alcohol and incubated in
1% H2O2 in water for 10 min to block endogenous peroxidase
activity. All washes were performed in 0.15M Tris-buffered
0.05M saline, pH 7.6 (TBS). Immunostaining was performed as
previously described in detail (Schiessl et al., 2009). Antibodies
were detected using an avidin-biotin-peroxidase technique
(Vectastain Elite ABC kit; Vector Laboratories, Peterborough,
United Kingdom). Details of source and dilution for all
antibodies are provided in Supplementary Table 1. The reaction
was developed for 1–2 min with 3,3′-diaminobenzidine (DAB;
Sigma Chemical Co. Dorset, United Kingdom) containing 0.01%
H2O2 to give a brown reaction product. Following this, sections
were lightly counterstained with Mayer’s hematoxylin for 30 s,
dehydrated, cleared in xylene and mounted with DPX synthetic
resin (Raymond A. Lamb Ltd., London, United Kingdom).
Positive and negative (replacement of the primary antibody by
appropriate non-immune serum) controls were performed for all
antibodies and samples.
Quantitative Image Analysis
Angiogenic Growth Factor (AGF) Expression in the
Endometrium
Sections were examined using a Nikon Eclipse 80i microscope
with a 20x objective and 10x eyepiece. AGF expression was
assessed in the endometrial vessels, stroma, and glands (N = 5)
in each of P/ES, MS/LS from both controls and women with
HMB, and MS/LS from women with RPL by an observer, who was
blinded to the origin of the sample using a modified “Quickscore”
method (Schiessl et al., 2009). The whole of each section was
assessed and the proportion of cells (1 = 0–25%, 2 > 25–50%,
3 > 50–75%, 4 > 75–100%) staining at a particular intensity
(0 = negative, 1 = weak, 2 = moderate, 3 = strong) was taken
into account. The percentage and intensity scores were then
multiplied and summed to give a possible score range of 0–
12. Vessels were identified by their smooth profile and by the
surrounding layer(s) of smooth muscle cells. Only vessels with
a visible lumen were included in the analysis.
VSMC Differentiation Marker Expression and ECM
Component Expression in Cultured Endometrium
Sections were examined using a Nikon Eclipse 80i microscope
with a 20x objective and 10x eyepiece. Expression of VSMC
differentiation markers, EC, and ECM components was assessed
in vessels in the entire tissue biopsies (N = 3 endometrium) in
the proliferative phase from controls by an observer, who was
blinded to the origin of the sample. Vessels were identified by
their smooth profile and by the surrounding layer(s) of smooth
muscle cells. Only vessels with a visible lumen were included in
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TABLE 1 | Patient information for control, heavy menstrual bleeding and recurrent pregnancy loss groups [Mean (range)].
Demographic criteria Control (n = 10) Heavy menstrual bleeding (n = 10) Recurrent pregnancy loss (n = 5)
Age (years) 41.1 (28–51) 41.8 (29–51) 38 (29–44)
Parity 2.9 (0–5) 2.2 (0–6) 0 (0–5)
Number of previous miscarriages 0 (0–1) 0 (0–1) 4 (3–7)
the analysis. Expression of VSMC differentiation markers and
vascular ECM components was assessed by counting manually
the percentage of vessels positively stained for each marker
compared with the total number of vessels in the entire tissue
as identified by CD31 + staining. VSMC differentiation marker
immunostaining intensity was assessed by modified “Quickscore”
as described above.
Isolation of Endothelial Cells and
Vascular Smooth Muscle Cells From
Saphenous Vein
Segments of saphenous vein (SV), obtained during coronary
bypass operation, ≥2 cm in length were used for isolation
of ECs and VSMCs. Veins were flushed with sterile PBS (pH
7.4) to remove red blood cells, one end constricted and filled
with warmed endothelial cell digestion medium (0.1% Type I
collagenase in PBS; Sigma), the other end was then constricted
and incubated for 15 min at 37◦C. The vein segment was
then flushed with 3–4 ml PBS (pH 7.4), the medium collected,
centrifuged (200 g for 5 min) and the resultant cell pellet
re-suspended in EC culture medium (EC Growth Kit-BBE in
vascular cell basal medium; LGC Standards Ltd, Teddington,
United Kingdom), plated into one well of a 6-well plate
and cultured at 37◦C. A second 40 min incubation in EC
digestion medium was performed and the resultant cell pellet
also re-suspended in EC culture medium and plated. A final
50 min incubation in VSMC digestion medium [0.1% Type
I collagenase, 0.02% elastase, 0.02% DNase in PBS (pH7.4);
Sigma] was performed, the resultant cell pellet re-suspended
in VSMC culture medium (Ham’s F12K containing 10% FBS,
30 µg/ml EC growth supplement, 50 µg/ml ascorbic acid, 1%
HEPES, 2.3 mg/ml TES, 1% insulin/transferrin/sodium selenite,
1% amphotericin, 1% penicillin/streptomycin; LGC Standards or
Sigma), plated in one well of a 6-well plate and incubated at
37◦C. After 24 h, medium in each well was replaced with 2 ml
appropriate EC or VSMC medium and incubated at 37◦C until
90% confluence was reached. Isolated cells were characterized by
immunocytochemistry for Factor VIII related antigen (F8RA),
CD31 and CD34 (ECs), and alpha-smooth muscle actin (αSMA),
h-caldesmon, and myosin heavy chain (VSMCs). Cells that
were >99% pure and were between passages 3 and 5 were used
for further experiments.
EC:VSMC Association Assay
ECs and VSMCs were incubated at 37◦C, 5% CO2 for 30 min
in cell tracker CFSE (5 mM stock diluted 1:5000 in EC basal
medium; Invitrogen) and CMRA (10 mM stock diluted 1:2000
in VSMC basal medium; Invitrogen), respectively. EC (6 × 103
cells/well) were plated into 8-well chambers slides, 4 wells of
which had been precoated with 5 µl growth factor reduced
Matrigel (BD) and incubated for 4.5 h at 37◦C at which point
VSMCs (6 × 103 cells/well) in cell media (0, 1, 10 ng/ml
TGFβ1) were added. Following a further 1 h incubation, time-
lapse live imaging was performed on a Nikon Eclipse-i laser-
scanning confocal microscope, equipped with 37◦C incubator
and 5% CO2 supply, using 20x oil objective, 10x eyepiece and
excitation wavelengths of 492 nm (CFSE) and 548 nm (CMRA).
Live imaging was carried out for up to 10 h and images
captured every 15 min.
In order to study EC:VSMC interaction on matrigel, the
following parameters were included: (a) total number of
honeycomb (or tubule) structures with ≥ 3 arms, (b) the
total number of nodes, (c) arm length, (d) the number of
complete honeycombs (with an enclosed area), (e) the perimeter
of the complete honeycombs, and finally (f) the percentage of
VSMC coverage of the complete honeycombs determined as
described below.
The digital time-lapse movies were analyzed using the
open-source ImageJ software package in combination with the
“cell counter” plugin to manually count the total number
of honeycombs, number of nodes, complete honeycombs and
measure the perimeter of three randomly chosen complete
honeycombs at t = 10 h and the length of 5 randomly chosen
arms at t = 10 h. The percentage of VSMC coverage was analyzed
by measuring the total length of one complete honeycomb
covered with VSMCs with respect to the EC perimeter length
of the honeycomb.
AGF Secretion
Saphenous vein-derived ECs and VSMCs were separately
cultured on 6-well plates and treated with TGFβ1 (0, 1, and 10
ng/ml) for 24 h. The resulting conditioned medium was harvested
and used to determine the relative levels of AGFs by ELISA
(VEGF-C, Ang-1, TGF-β1; R&D Systems Ltd) or Quantibody
multiplex array (Angiogenin, Ang-2, EGF, bFGF, HB-EGF,
HGF, Leptin, PDGF-BB, PlGF, VEGF-A; Raybiotech, Norcross,
United States) according to the manufacturers’ instructions. Each
experiment was performed on three separate occasions.
Statistical Analysis
Statistical analyses were performed using SPSS version 15.0 (SPSS
Inc.). Data are presented as means ± standard error of mean
(SEM) and differences were considered statistically significant at
P ≤ 0.05. For comparison of three or more groups, Kruskal–
Wallis or ANOVA with post hoc tests were used for non-
parametric or parametric data as appropriate. For comparison
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of 2 groups Mann–Whitney U or Students t test were used for
non-parametric or parametric data as appropriate.
RESULTS
Factors Involved in TGFβ1 Activation
There was weak to moderate immunoreactivity for LTBP1 in the
stroma, glandular epithelium and vessels of the endometrium
that did not alter across the menstrual cycle on in cases of HMB or
RPL (Figures 1A,B). THBS1 showed moderate immunoreactivity
in the endometrial stroma, glandular epithelium and vessels
that did not alter across the menstrual cycle in control women
or in women with HMB (Figures 1A,B). However, THBS1
immunoreactivity was increased in the stroma (P < 0.001),
glandular epithelium (P < 0.05) and vessels (P < 0.01) of
women with RPL compared with control women in the MS/LS
phase of the menstrual cycle (Figures 1A,B). MMP2 showed
weak to moderate immunoreactivity in the endometrial stroma,
glandular epithelium, and vessels that did not alter with the
menstrual cycle in control women or in women with RPL
(Figures 1A,B). In MS/LS endometrium of women with HMB,
MMP2 immunoreactivity was increased compared with controls
(Stroma P < 0.05, glandular epithelium P < 0.05, vessels
P < 0.05) (Figures 1A,B). Immunoreactivity for MMP9 was
weak in all sections of the endometrium examined and did not
alter with the menstrual cycle in control women or in women
with HMB (Figures 1A,B); however, in comparison, women with
RPL demonstrated an increase in MMP9 immunoreactivity in the
endometrial vessels (P < 0.05) (Figures 1A,B).
TGFβ1 and Receptors
We have previously reported that immunoreactivity for TGFβ1
is increased in the endometrium of women with RPL, while
TGFβRI and TGFβRII are decreased (Lash et al., 2012). In
the current study immunoreactivity for TGFβ1 was weak to
moderate and was increased in the vessels of control women in
the MS/LS phase of the menstrual cycle compared to the P/ES
phase (P< 0.001) (Figures 2A,B). Stromal immunoreactivity was
reduced in the P/ES phase of women with HMB compared with
controls (P < 0.05), and in women with HMB was increased
in the MS/LS phase compared with the P/ES phase (P < 0.05)
(Figures 2A,B). Immunoreactivity for TGFβRI and TGFβRII was
also weak to moderate and did not alter with the menstrual
cycle in control women or women with HMB (Figures 2A,B).
Vascular immunoreactivity for TGFβRI was reduced in women
with HMB in both the P/ES (P < 0.01) and MS/LS (P < 0.05)
phases of the menstrual cycle compared with controls. Glandular
immunoreactivity was also reduced in the MS/LS phase of HMB
women compared with controls (P < 0.01) (Figures 2A,B).
In addition, stromal (P < 0.01) and vascular (P < 0.05)
immunoreactivity for TGFβRII was reduced in P/ES phase of the
menstrual cycle of women with HMB compared with controls
(Figures 2A,B).
Immunoreactivity for ALK4 was weak to moderate in all
cell types and was reduced in the stroma of control women
in the MS/LS phase of the menstrual cycle compared to the
P/ES phase (P < 0.01), but was increased in both the glandular
epithelium (P < 0.01) and vessels (P < 0.05) (Figures 3A,B). In
addition, ALK4 was increased in stroma (P < 0.01) and vessels
(P < 0.05) in the MS/LS phase of the menstrual cycle of women
with HMB compared with the P/ES phase. In the P/ES phase of
the cycle of women with HMB, ALK4 immunoreactivity in the
stroma was reduced compared with the control samples from
the same cycle phase (P < 0.01). In the MS/LS of women with
HMB, ALK4 immunoreactivity in the glandular epithelium was
reduced compared to controls (P< 0.05). In the MS/LS of women
with RPL, ALK4 immunoreactivity in the stroma was increased
compared to controls (P < 0.01). ALK7 immunoreactivity was
weak to moderate in the stroma, glandular epithelium and vessels
and did not alter across the menstrual cycle of controls, or in
women with HMB or RPL (Figures 3A,B).
Immunoreactivity for integrin αv was weak in stroma,
glandular epithelium, and vessels, which was increased in
the stroma in the MS/LS phase of controls compared with
the P/ES phase (P < 0.05) (Figures 4A,B). In the P/ES
phase glandular epithelium of women with HMB, integrin
αv immunoreactivity was increased compared to controls
(P < 0.05). In RPL, integrin αv immunoreactivity in stroma
was decreased (P < 0.01), but increased in glandular epithelium
(P < 0.05) and vessels (P < 0.01) compared to controls.
Integrin β3 immunoreactivity was weak in stroma, glandular
epithelium, and vessels that did not alter across the menstrual
cycle of controls (Figures 4A,B). In women with HMB
and RPL MS/LS, immunoreactivity of integrin β3 in stroma
(HMB P < 0.05, RPL P < 0.01) and glandular epithelium
(HMB P < 0.05, RPL P < 0.01) was increased compared to
controls; in RPL vessel (P < 0.05), immunoreactivity was also
increased compared to controls. Integrin β6 immunoreactivity
in stroma, glandular epithelium, and vessels was weak and
did not change across the menstrual cycle (Figures 4A,B).
In the P/ES phase of the menstrual cycle in women with
HMB immunoreactivity for integrin β6 in glandular epithelium
(P < 0.05) and vessels (P < 0.05) was increased compared
with controls, while stromal immunoreactivity was increased
in the MS/LS phase of the menstrual cycle (P < 0.05)
(Figures 4A,B). In women with RPL glandular epithelial
immunoreactivity of integrin β6 was increased compared to
controls (P < 0.05).
TGFβ1 Signaling Pathway
Immunoreactivity for Smad2 was weak to moderate in
endometrial stroma, glandular epithelium and vessels, which
did not alter across the menstrual cycle of controls or in women
with HMB or RPL (Figures 5A,B). Moderate immunostaining
for Smad3 was observed in stroma, glandular epithelium and
vessels, and did not alter across the menstrual cycle in controls
(Figures 5A,B). Smad3 immunoreactivity was reduced in MS/LS
phase stroma (P < 0.01), glandular epithelium (P < 0.05) and
vessels (P < 0.05) in women with HMB compared to controls,
stromal Smad3 was also reduced in women with RPL (P < 0.05)
(Figures 5A,B). Smad4 immunoreactivity was weak to moderate
in stroma, glandular epithelium, and vessels and increased
in glandular epithelium of controls (P < 0.05) and HMB
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FIGURE 1 | (A) Representative photomicrographs of immunostaining for large latent TGFβ-binding protein (LTBP1), thrombospondin (THBS1), matrix
metalloproteinase (MMP)2 and MMP9 in proliferative/early secretory (P/ES), mid/late secretory (MS/LS) phase of the menstrual cycle in control and women with
heavy menstrual bleeding (HMB), and MS/LS phase of women with recurrent pregnancy loss (RPL). Scale bar = 200 µm. Insets show enlarged magnification of one
endometrial blood vessel. (B) Histograms showing quickscore for LTBP1, THBS1, MMP2, and MMP9 in endometrial stromal cells, glandular epithelium and blood
vessels (EC + VSMC) n = 5 each group. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
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FIGURE 2 | (A) Representative photomicrographs of immunostaining for TGFβ1, TGFβRI, and TGFβRII in proliferative/early secretory (P/ES), mid/late secretory
(MS/LS) phase of the menstrual cycle in control and women with heavy menstrual bleeding (HMB), and MS/LS phase of women with recurrent pregnancy loss (RPL).
Scale bar = 200µm. Insets show enlarged magnification of one endometrial blood vessel. (B) Histograms showing quickscore for TGFβ1, TGFβRI, and TGFβRII in
endometrial stromal cells, glandular epithelium and blood vessels (EC + VSMC) n = 5 each group. * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
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FIGURE 3 | (A) Representative photomicrographs of immunostaining for activin-like receptor (ALK)4 and ALK7 in proliferative/early secretory (P/ES), mid/late
secretory (MS/LS) phase of the menstrual cycle in control and women with heavy menstrual bleeding (HMB), and MS/LS phase of women with recurrent pregnancy
loss (RPL). Scale bar = 200 µm. Insets show enlarged magnification of one endometrial blood vessel. (B) Histograms showing quickscore for ALK4 and ALK7 in
endometrial stromal cells, glandular epithelium and blood vessels (EC + VSMC) n = 5 each group. * = P < 0.05, ** = P < 0.01.
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FIGURE 4 | (A) Representative photomicrographs of immunostaining for integrins αv, β3, and β6 in proliferative/early secretory (P/ES), mid/late secretory (MS/LS)
phase of the menstrual cycle in control and women with heavy menstrual bleeding (HMB), and MS/LS phase of women with recurrent pregnancy loss (RPL). Scale
bar = 200 µm. Insets show enlarged magnification of one endometrial blood vessel. (B) Histograms showing quickscore for integrins αv, β3, and β6 in endometrial
stromal cells, glandular epithelium and blood vessels (EC + VSMC) n = 5 each group. * = P < 0.05, ** = P < 0.01.
(P < 0.05) in MS/LS compared with P/ES phase endometrium
(Figures 5A,B). Vessel immunoreactivity of Smad4 was reduced
in MS/LS phase in both women with RPL (P < 0.05) and HMB
(P < 0.05) compared to controls (Figures 5A,B). Moderate
immunoreactivity for Smad7 was observed in stroma, glandular
epithelium, and vessels and did not alter across the menstrual
cycle of controls or in women with HMB (Figures 5A,B).
Immunoreactivity for Smad7 was reduced in both endometrial
glandular epithelium (P < 0.05) and vessels (P < 0.05) of women
with RPL compared with controls (Figures 5A,B).
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FIGURE 5 | (A) Representative photomicrographs of immunostaining for Smad2, Smad3, Smad4, and Smad7 in proliferative/early secretory (P/ES), mid/late
secretory (MS/LS) phase of the menstrual cycle in control and women with heavy menstrual bleeding (HMB), and MS/LS phase of women with recurrent pregnancy
loss (RPL). Scale bar = 200 µm. Insets show enlarged magnification of one endometrial blood vessel. (B) Histograms showing quickscore for Smad2, Smad3,
Smad4, and Smad7 in endometrial stromal cells, glandular epithelium, and blood vessels (EC + VSMC) n = 5 each group. * = P < 0.05, ** = P < 0.01.
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Effect of TGFβ1 on Endometrial Vascular
Development
To determine whether TGFβ1 plays a role in endometrial vascular
development small endometrial biopsies were cultured in TGFβ1
or anti-TGFβ1 and assessed by immunohistochemistry for the
total number of CD31+ vessels, the percentage of CD31+ vessels
that also expressed VSMC markers or ECM components, and the
intensity of immunoreactivity of those markers. Representative
photomicrographs are shown in Figure 6.
The total number of CD31+ endometrial vessels did not
alter after treatment with TGFβ1 (10 ng/ml) or anti-TGFβ1
(10 ng/ml) (control 7.3 ± 2.7; TGFβ1 6.9 ± 3.6; anti-TGFβ1
6.6 ± 4.3). Around 30% CD31+ endometrial vessels also
expressed h-caldesmon in the untreated control group. This
was reduced when treated with either TGFβ1 (∼20%) or
anti-TGFβ1 (∼12%) compared with the untreated group. The
immunoreactivity of h-caldesmon did not alter with treatment
(control 2.0 ± 0; TGFβ1 3.0 ± 0; anti-TGFβ1 4.0 ± 1.0). Around
10% CD31+ endometrial vessels also expressed smoothelin in
the untreated control group, that was reduced after treatment
with TGFβ1 (< 5%) or anti-TGFβ1 (< 5%). Smoothelin
immunoreactivity intensity was not altered by treatment (control
1.0 ± 1.0; TGFβ1 1.0 ± 1.0; anti-TGFβ1 2.0 ± 2.0). Around
15% CD31+ endometrial vessels also expressed calponin, which
was reduced after treatment with TGFβ1 (< 5%) or anti-TGFβ1
(< 5%). However, the immunoreactivity intensity for calponin
was not altered (control 2.5 ± 0.5; TGFβ1 2.5 ± 0.5; anti-TGFβ1
2.0 ± 1.0). In the endometrial explants, all of the CD31+ vessels
expressed collagen IV and osteopontin in the untreated control
group, which was unaltered after treatment with TGFβ1 (100%)
or anti-TGFβ1 (100%). The immunoreactivity intensity was also
unaltered by treatment (collagen IV: control 9.0 ± 1.0; TGFβ1
9.5 ± 1.5; anti-TGFβ1 10.5 ± 1.5; osteopontin: control 8.0 ± 0;
TGFβ1 7.5± 0.5; anti-TGFβ1 8.0± 1.0).
Effect of TGFβ1 on EC:VSMC Association
in vitro
To determine how TGFβ1 effects the association of EC and
VSMCs, we developed an in vitro assay extension of the
commonly used EC tubule formation assay (Figure 7A). In
addition to assessing the total number of honeycombs formed
and the average length of the perimeter of each honeycomb, the
% of honeycomb length covered by VSMCs was also determined.
The total number of nodes and arm lengths were also assessed
but this did not alter with treatment (data not shown). Treatment
with TGFβ1 reduced the total number of honeycombs after 10
h (1 ng/ml, P = 0.005; 10 ng/ml P = 0.002) (Figure 7B), and
the perimeter length (1 ng/ml, P = 0.01; 10 ng/ml, P = 0.005)
(Figure 7C). However, it also increased the percentage of EC
honeycombs covered by VSMCs (1 ng/ml, P = 0.04; 10 ng/ml,
P = 0.04) (Figure 7D).
To determine the potential mechanism by which TGFβ1 might
increase EC:VSMC association secretion of a range of angiogenic
growth factors by EC or VSMC after treatment with TGFβ1
was assessed by multiplex assay. Neither EC or VSMC secreted
detectable levels of leptin, EGF or HB-EGF, and VSMC did not
have detectable levels of VEGF-C. Treatment of EC with TGFβ1
did not alter secretion levels of any of the proteins investigated
(Figure 7E). Treatment of VSMC with TGFβ1 only increased the
secretion of TGFβ1 itself (10 ng/ml, P = 0.01, Figure 7F).
DISCUSSION
Both HMB and RPL are associated with alterations in
endometrial vascular development. In the current study, we
demonstrate dysregulation of TGFβ1 and associated activation
and signaling pathway proteins in the endometrium of
women with HMB or RPL compared with normal controls.
TGFβ1 is one of the key growth factors that drives VSMC
maturation, and using an in vitro EC:VSMC association assay,
we demonstrate an increased association of VSMCs with pre-
existing EC tubules after treatment with TGFβ1. This is one
of the most comprehensive immunohistochemical studies of
TGFβ1 binding and signaling pathway components in the
normal and pathological endometrium and will give us insights
into the importance of this growth factor in endometrial
regeneration and pathology.
Angiogenesis and vascular development take place in the
endometrium across the menstrual cycle through elongation of
vascular stubs in the endometrium basalis, which were left after
menstrual shedding of the endometrium functionalis (Girling
and Rogers, 2005, 2009). While the process of blood vessel
growth and development in endometrium remains under the
master control of steroid hormones, angiogenic growth factors
such as TGFβ1 and its receptors may directly regulate EC
proliferation and/or apoptosis, interaction with and integrity of
ECM components, as well as recruitment and maturation of
VSMCs, which ultimately results in vascular development and
maturation (Dickson et al., 1995; Pepper, 1997; Massague et al.,
2000; Tabibzadeh, 2002; Distler et al., 2003). The majority of
TGFβ1 is found as a latent form bound to latency associated
proteins and then often also held within the ECM close to
the cell membrane by different integrins. When required, it
can be activated by proteases or thrombospondin and bind to
TGFβRII, which recruits TGFβRI or the alternative receptors
ALK4 and ALK7, thereby setting up the Smad signaling pathway
involving phosphorylation of Smads2, 3, 4, and 7, with eventual
nuclear translocation of p-Smad4 and transcription regulation.
Therefore, alteration in the expression of any of these factors will
lead to aberrant vascular development, dependent on the balance
of direction of change for all these pathway components.
In HMB, we and others have shown a failure in vascular
maturation in the mid-late secretory phase of the menstrual cycle
(Abberton et al., 1999b; Biswas Shivhare et al., 2014; Biswas
Shivhare et al., 2018). In the current study, we demonstrate that in
women with HMB, there was no change in the immunoreactivity
for LTBP1, THBS1, or MMP9 in any of the cell types investigated.
However, MMP2 immunoreactivity in stromal cells, glandular
epithelium, and vessels was increased suggesting a potential
increase in bioactive TGFβ1. However, there was a decrease in
immunoreactivity in TGFβ1 (stromal cells), TGFβRI (glandular
epithelium and vessels), TGFβRII (stromal cells and vessels),
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FIGURE 6 | Representative photomicrographs of TGFβ1 (10 ng/ml) and anti-TGFβ1 (10 ng/ml) treated proliferative endometrium explants immunostained for CD31,
h-caldesmon, osteopontin, collagen IV. Scale bar = 200 µm.
and ALK4 (stromal cells and glandular epithelium), which
together suggest lowered levels of TGFβ1 and availability of
both classical and alternative receptors. In particular, lowered
stromal cell TGFβ1 and reduced vascular immunoreactivity for
both TGF receptors would suggest a decrease in bioactivity in
the maturing vasculature. In addition, there was an increase in
the immunoreactivity of integrins β3 (stromal cells and glandular
epithelium) and β6 (stromal cells and vessels), which bind active
TGFβ1 making it available for receptor binding. Finally, there
was decreased immunoreactivity for Smad3 (all cell types) and
Smad4 (vessels), suggesting a decrease in signaling capacity,
particularly in the developing vasculature. These data suggest an
overall decrease in TGFβ1, subsequent receptor, and signaling
capacity predominantly localized to the vasculature and thereby
contributing to the decreased vascular maturation observed in
women with HMB (Figure 8A). In contrast, Rae et al. (2009)
demonstrated a decrease in mRNA for THBS1 in women with
HMB compared with controls. In vitro studies suggested that the
reduced THBS1 was due to an inactivation of cortisol, and both
THBS1 and cortisol led to increased tubule formation of ECs (Rae
et al., 2009). In addition to its ability to activate latent TGFβ1
in a non-proteolytic manner, THBS1 is also an angiogenesis
inhibitor. However, in our experience, HMB is not associated
with dysregulated angiogenesis but with a failure of maturation
of the endometrial blood vessels, leading to premature and
extended bleeding and menstrual shedding that may also be
associated with hypoxia due to this failure to develop an adequate
vascular environment (Maybin et al., 2018). Two other studies
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FIGURE 7 | (A) Representative photomicrographs of EC tubules (green) covered by VSMCs (red) in control and TGFβ1 (1 and 10 ng/ml) treated wells (10 h). (B–D)
Graphical representation of endothelial cell honeycomb number (B), honeycomb perimeter length (C) and percentage VSMC coverage of the EC tubules (D) in the
VSMC:EC association assay after treatment with TGFβ1 for 10 h. (E,F) EC (E) and VSMC (F) secretion of a range of angiogenic growth factors after TGFβ1
treatment. N = 5 all conditions. Data are shown as mean ± SD.
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FIGURE 8 | Pictorial representation of the overall changes in immunoreactivity stromal cells, glandular epithelium, and vessels in the endometrium of women with
HMB (A) or RPL (B). Note that for simplicity, immune cells have not been depicted in the stroma, and only factors which demonstrated significant differences in
immunoreactivity have been shown.
have previously investigated TGFβ1 and associated proteins in
the endometrium of HMB with varying results. Abberton et al.
(1999b) demonstrated no difference in TGFβ1 immunoreactivity
in an immunohistochemical study of endometrium from control
women and those with HMB. More recently, Maybin et al. (2017)
reported no difference in mRNA levels for TGFβ1, TGFβRI,
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or TGFβRII in endometrium of women with HMB compared
with controls. However, they did demonstrate a decrease in
immunoreactivity for TGFβ1 in the stromal cells of women
with HMB compared with controls. In addition, they also
demonstrated a decrease in Smad2 and Smad3 mRNA and levels
of their corresponding phosphoproteins in women with HMB.
The findings of the current study are more consistent with
those of Maybin et al. (2017), and any differences may be due
to differences in methodology, menstrual cycle groupings, and
classification of HMB. Maybin et al. (2017) used an empirical
definition of HMB with 80 mL menstrual blood loss as the cut
off, whereas blood loss was not objectively measured in our
study, and we used the current clinical assessment of patient
declared HMB; thus, the classification used in the current study
was more subjective.
In contrast to HMB, we and others have shown increased
endometrial vascular maturation in women with RPL (Quenby
et al., 2009; El-Azzamy et al., 2018). We had also previously
shown that immunoreactivity for TGFβ1 (vessels) was increased,
and both TGFβRI (stromal cells, glandular epithelium, and
vessels) and TGFβRII (vessels) decreased in the endometrium of
women with RPL compared to controls (Lash et al., 2012). In the
current study, we also show an increase in both THBS1 (all cell
types) and MMP9 (vessels), suggesting an increase in both the
non-proteolytic and proteolytic pathways for TGFβ1 activation
in the developing vasculature. In addition, immunoreactivity
for the alternative receptor ALK4 (stromal cells) was increased,
as were the integrins β3 (stromal cells and vessels) and β6
(glandular epithelium). Immunoreactivity for integrin αv had
variable expression, was increased in the glandular epithelium
and vessels, but reduced in stromal cells. These data suggest
potential increased bioavailability of and binding capacity for
TGFβ1. In addition, immunoreactivity for Smad3 (stromal cells),
4 (vessels), and 7 (glandular epithelium and vessels) were all
decreased in women with RPL. Taken together, these data suggest
an increase in bioactive TGFβ1 in and near the vasculature,
although signaling capacity may be reduced. The observed
increase in bioactive TGFβ1 likely contributes to the increased
vascular maturation observed in women with RPL (Figure 8B).
Using two different in vitro models, culture of endometrial
explants and a novel EC:VSMC association assay, it was also
demonstrated that treatment with TGFβ1 increased recruitment
of VSMCs to the endometrial vasculature as well as their
differentiation into a more contractile phenotype. In addition,
TGFβ1 increased TGFβ1 secretion by VSMCs, but not ECs,
and did not alter secretion of any other factor investigated
suggesting the existence of a positive regulation loop for vascular
TGFβ1 expression. TGFβ1 is the best described growth factor
driving the differentiation of the phenotypically plastic VSMCs
from the synthetic state to the more mature contractile state.
VSMC phenotypic switching is primarily regulated by the master
transcription factors mycodelin and KLF4, with mycodelin
driving differentiation to a contractile state and KLF4 driving
the reverse. TGFβ1 can regulate mycodelin expression either
directly via the Smad pathway or via regulation of different
miRNA species (Chan et al., 2010; Davis-Dusenbery et al., 2011;
Lim et al., 2020).
One limitation of the current study is that is uses
semiquantitative immunohistochemical scoring to assess
expression levels of the investigated proteins. However, the
advantage of this technique is that we can assess different
cellular components separately, and as was revealed, changes
in the expression patterns were often cell specific, and these
results may have been masked by whole tissue Western Blot
or qPCR studies (Maclean et al., 2020). The second limitation
is the use of subjective measurement criteria for HMB; while
these criteria are in line with NICE guidelines (2018) and are
in accordance with routine clinical practice, it is possible that
some of our patients did not have greater than 80 mL blood
loss and that some of our control women did but had not
reported HMB symptoms. However, since the women were
undergoing a major surgery, a hysterectomy, for their HMB,
we believe our HMB group was a clinically suitable group
to study.
Taken together, the data presented in the current study suggest
that TGFβ1 is a key regulatory pathway for vascular maturation
in the endometrium across the menstrual cycle, and when this
pathway is dysregulated, it contributes to the altered vascular
development observed in conditions such as HMB and RPL.
However, we still do not understand how the TGFβ1 pathway
is regulated in the endometrium, and studies are currently
underway in our laboratories to investigate the role of miRNA
in the regulation of this pathway in both HMB and RPL.
Manipulation of the TGFβ1 pathway maybe a viable option for
the treatment of both HMB and RPL in women who wish to
preserve their fertility, especially as the development of TGFβ1
pathway modulators is already being explored for the treatment
of metastatic cancer, with the possibility of repurposing of these
therapeutics for the treatment of women with HMB and/or
RPL, although any treatment in the latter group would need to
be pre-pregnancy.
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